# Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer

> **NCT03759496** · PHASE2 · UNKNOWN · sponsor: **Hellenic GenitoUrinary Cancer Group** · enrollment: 39 (estimated)

## Conditions studied

- Bladder Cancer

## Interventions

- **BIOLOGICAL:** Durvalumab

## Key facts

- **NCT ID:** NCT03759496
- **Lead sponsor:** Hellenic GenitoUrinary Cancer Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-15
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2022-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03759496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03759496, "Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03759496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*